Company intelligence / Profile preview
Eiger BioPharmaceuticals, Inc.
Palo Alto, California, United Statesorpha.net ↗
- Ownership
- Public · EIGR
- Employees
- ~25
- Development stage
- Commercial
01
Overview
Eiger commercialized Zokinvy® for progeria syndromes and advanced several late-stage clinical programs including lonafarnib for hepatitis delta virus infection and avexitide for metabolic disorders. The company faced financial difficulties after suspending a key Phase III trial in late-stage development due to safety concerns. In April–September 2024 it filed for Chapter 11 bankruptcy protection and began selling off its assets.[1][2][5]
- Therapeutic areas
- EndocrinologyRare DiseasesInfectious Diseases
- Modalities
- small molecules[9]biologics/interferons[9]
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Engaged with Amylyx Pharmaceuticals for Avexitide asset salepreviously collaborated with The Progeria Research Foundation on Zokinvy® approval/licensing.[1]
04
Financials
- Market cap
- $2.6M
- Total revenue
- $3.8M
- Enterprise value
- $18.3M
Beyond the preview
Go deeper on Eiger BioPharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eiger BioPharmaceuticals, Inc..